Daniel V Araujo

Daniel V Araujo, MD

CLIN ASO PROF

Department: MD-HEMATOLOGY/ONCOLOGY
Business Phone: (352) 273-7832
Business Email: daniel.araujo@ufl.edu

About Daniel V Araujo

Dr. Daniel V. Araujo is a medical oncologist specializing in genitourinary malignancies—including renal cell carcinoma, bladder cancer, prostate cancer, testicular cancer—as well as melanoma and other skin cancers.

He earned his medical degree from Universidade Federal da Paraíba (UFPB) in Brazil, followed by an internal medicine residency at UNESP Botucatu and a medical oncology residency at the AC Camargo Cancer Center. He later completed a fellowship in Drug Development at the Princess Margaret Cancer Centre, University of Toronto, with a clinical focus on genitourinary and skin malignancies.

Dr. Araujo’s research interests center on early-phase clinical trials, cancer drug development, dose optimization, trial design, and evidence synthesis through systematic reviews and meta-analyses. He is deeply committed to advancing cancer care while ensuring that patients receive compassionate, personalized, and evidence-based treatment throughout their journey.

Prior to joining UF Health, Dr. Araujo was an Assistant Professor at the University of British Columbia and a medical oncologist at BC Cancer – Abbotsford, Canada. He also served as Head of Medical Oncology at Hospital de Base in São José do Rio Preto, Brazil, and as faculty member at the AC Camargo Cancer Center, where he led initiatives in multidisciplinary care and clinical research. He continues to supervise and collaborate on academic projects at both national and international levels.

Fluent in English and Portuguese, Dr. Araujo is passionate about medical education, mentorship, and collaborative oncology networks. Outside of medicine, he enjoys spending time with his wife and two daughters, playing tennis, and cheering for his favorite Brazilian soccer teams.

Clinical Profile

Specialties
  • Medical Oncology
Areas of Interest
  • Bladder Cancer
  • Melanoma
  • Prostate Cancer
  • Renal cell carcinoma
  • Skin Cancer
  • Testicular Cancer
  • Urologic Cancer

Publications

Academic Articles
2024
Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update
Journal of Cancer Research and Clinical Oncology. 150(4) [DOI] 10.1007/s00432-024-05663-z. [PMID] 38594593.
2024
Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients
ESMO Open. 9(11) [DOI] 10.1016/j.esmoop.2024.103978. [PMID] 39549683.
2023
First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)
Annals of Oncology. 34(6):520-530 [DOI] 10.1016/j.annonc.2023.02.011.
2023
Oncology phase I trial design and conduct: time for a change – MDICT Guidelines 2022
Annals of Oncology. 34(1):48-60 [DOI] 10.1016/j.annonc.2022.09.158.
2023
Prescription pattern of abiraterone in Brazil – a survey of medical oncologists
Brazilian Journal of Oncology. 19(CP) [DOI] 10.5935/2526-8732.20230413.
2023
Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical Trials
JCO Precision Oncology. (7) [DOI] 10.1200/po.22.00509.
2022
A risk stratification model for toxicities in phase 1 immunotherapy trials
European Journal of Cancer. 175:11-18 [DOI] 10.1016/j.ejca.2022.08.003.
2022
Assessing Oncologists’ Attitudes Concerning Comprehensive Genomic Profiling in Stage IV Lung Adenocarcinoma in Brazil
JTO Clinical and Research Reports. 3(10) [DOI] 10.1016/j.jtocrr.2022.100402. [PMID] 36193188.
2022
Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials
European Journal of Cancer. 173:167-177 [DOI] 10.1016/j.ejca.2022.06.045.
2022
Patient-centered trials in oncology: Time for a change
Med. 3(7):445-449 [DOI] 10.1016/j.medj.2022.06.007.
2022
When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents
Targeted Oncology. 17(3):253-270 [DOI] 10.1007/s11523-022-00890-1.
2021
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study
Journal for ImmunoTherapy of Cancer. 9(10) [DOI] 10.1136/jitc-2021-003476. [PMID] 34599023.
2021
Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy
JNCI Cancer Spectrum. 5(3) [DOI] 10.1093/jncics/pkaa122. [PMID] 34056539.
2021
Beyond immune checkpoint blockade: emerging immunological strategies
Nature Reviews Drug Discovery. 20(12):899-919 [DOI] 10.1038/s41573-021-00155-y.
2021
Bugs as drugs: The role of microbiome in cancer focusing on immunotherapeutics
Cancer Treatment Reviews. 92 [DOI] 10.1016/j.ctrv.2020.102125.
2021
CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus
Cancers. 14(1) [DOI] 10.3390/cancers14010089. [PMID] 35008256.
2021
Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era
European Journal of Cancer. 158:85-98 [DOI] 10.1016/j.ejca.2021.09.016.
2021
Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors
Cancers. 13(14) [DOI] 10.3390/cancers13143640. [PMID] 34298857.
2021
Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis
Journal of Geriatric Oncology. 12(5):820-826 [DOI] 10.1016/j.jgo.2021.02.022.
2021
Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor‒Like Melanoma
Journal of Investigative Dermatology. 141(10):2470-2479 [DOI] 10.1016/j.jid.2021.03.016.
2021
Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events
Current Oncology. 28(3):2173-2179 [DOI] 10.3390/curroncol28030201. [PMID] 34208089.
2021
Systematic SARS-CoV-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in Brazil
ecancermedicalscience. 15 [DOI] 10.3332/ecancer.2021.1269. [PMID] 34567254.
2021
The Day After COVID-19—Time to Rethink Oncology Clinical Research
JAMA Oncology. 7(1) [DOI] 10.1001/jamaoncol.2020.4240.
2019
Characteristics of Immune Checkpoint Inhibitors Trials Associated With Inclusion of Patients With HIV
JAMA Network Open. 2(11) [DOI] 10.1001/jamanetworkopen.2019.14816. [PMID] 31702796.
2019
Complete metastasectomy in renal cell carcinoma: a propensity-score matched by the International Metastatic RCC Database Consortium prognostic model
ecancermedicalscience. 13 [DOI] 10.3332/ecancer.2019.967. [PMID] 31921338.
2019
Designing circulating tumor DNA-based interventional clinical trials in oncology
Genome Medicine. 11(1) [DOI] 10.1186/s13073-019-0634-x. [PMID] 31003596.
2019
The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma
Medical Oncology. 36(1) [DOI] 10.1007/s12032-018-1234-0.
2016
MRP1 expression in CTCs confers resistance to irinotecan‐based chemotherapy in metastatic colorectal cancer
International Journal of Cancer. 139(4):890-898 [DOI] 10.1002/ijc.30082.
2015
Thymidylate synthase expression in circulating tumor cells: A new tool to predict 5‐fluorouracil resistance in metastatic colorectal cancer patients
International Journal of Cancer. 137(6):1397-1405 [DOI] 10.1002/ijc.29495. [PMID] 25721610.

Education

Fellowship in Drug Development
2018-2020 · Princess Margaret Cancer Centre, Canada
Medical Oncology Residency
2013-2016 · AC Camargo Cancer Center, Brazil
Internal Medicine Residency
2011-2013 · UNESP – Botucatu
MD
2005-2010 · Universidade Federal da Paraiba (UFPB), Brazil

Contact Details

Phones:
Business:
(352) 273-7832
Emails:
Addresses:
Business Mailing:
PO Box 100278
GAINESVILLE FL 32610
Business Street:
2033 MOWRY RD STE 145
GAINESVILLE FL 32610